Hudson Bay Capital Management LP Has $11.66 Million Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Hudson Bay Capital Management LP lifted its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 27.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 920,108 shares of the company’s stock after buying an additional 200,000 shares during the period. Hudson Bay Capital Management LP owned about 0.91% of Day One Biopharmaceuticals worth $11,658,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. FMR LLC increased its holdings in Day One Biopharmaceuticals by 73.9% in the fourth quarter. FMR LLC now owns 12,887,467 shares of the company’s stock valued at $163,284,000 after purchasing an additional 5,475,087 shares during the period. Alyeska Investment Group L.P. acquired a new stake in Day One Biopharmaceuticals in the fourth quarter valued at $31,829,000. Boxer Capital Management LLC acquired a new stake in Day One Biopharmaceuticals in the fourth quarter valued at $15,077,000. Marshall Wace LLP acquired a new stake in Day One Biopharmaceuticals in the fourth quarter valued at $13,909,000. Finally, Estuary Capital Management LP increased its holdings in Day One Biopharmaceuticals by 35.5% in the fourth quarter. Estuary Capital Management LP now owns 3,716,777 shares of the company’s stock valued at $47,092,000 after purchasing an additional 972,997 shares during the period. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Day One Biopharmaceuticals

In related news, CEO Jeremy Bender sold 12,048 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $144,094.08. Following the transaction, the chief executive officer now owns 128,015 shares of the company’s stock, valued at approximately $1,531,059.40. This trade represents a 8.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Adam Dubow sold 4,646 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $55,566.16. Following the completion of the transaction, the general counsel now directly owns 39,602 shares in the company, valued at approximately $473,639.92. The trade was a 10.50% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 21,064 shares of company stock valued at $251,925 in the last 90 days. 6.20% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on DAWN shares. JPMorgan Chase & Co. decreased their price objective on Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a report on Wednesday, March 5th. HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. Wedbush reaffirmed an “outperform” rating and set a $25.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, May 7th. Needham & Company LLC cut their price target on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. Finally, The Goldman Sachs Group cut their price target on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating on the stock in a research report on Tuesday, March 25th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $30.57.

Day One Biopharmaceuticals Price Performance

DAWN stock opened at $6.45 on Monday. The stock has a market capitalization of $653.78 million, a PE ratio of -6.26 and a beta of -1.24. The company’s 50-day moving average is $7.70 and its 200-day moving average is $11.05. Day One Biopharmaceuticals, Inc. has a 1 year low of $6.26 and a 1 year high of $17.14.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.11. The company had revenue of $30.76 million for the quarter, compared to the consensus estimate of $30.28 million. On average, analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.